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The STem Cell ConneCTion of Primary Brain TumorS
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Gliomas account for more than half of adult primary intracranial tumors, with anaplastic astrocytomas and glioblastoma 
multiforme (also known as malignant gliomas) being the most common. Plethora of evidence supports the notion that 
malignant glioma and other types of primary brain tumors arise from cells with stem cell/progenitor cell properties. To 
designate this cellular population a novel term has been introduced: glioma stem cells. These cells form a small subset of 
all cancer cells and share some features of normal stem cells, e.g. a capacity for self-renewal, multipotency and relative 
quiescence. These chemo- and radiation resistant cells are mainly responsible for maintaining tumor volume leading to therapy 
failure and recurrence. This review summarizes new findings on the interaction between the glioma stem cells, the tumor 
micro-environment, and specific cancer-causing genetic changes in the evolution of primary central nervous system tumors. 
Biomed Rev 2009; 20: 31–39.
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inTroDuCTion
Stem cells are defined by the ability to self renew and give 
rise to specified cell types. They have been attracting a lot of 
public attention in regard to the prospective for developing 
novel therapies for yet incurable diseases. Specifically, neu-
ral stem cells (central nervous system, CNS stem cells) have 
demonstrated an in vivo and in vitro capacity to differentiate 
into neurons, astrocytes and oligodendrocytes and have be-
come candidates for cell replacement therapies in neurode-
generative, demyelinating and other disorders of the central 
nervous system (CNS). Interestingly, CNS stem cells have 
proven to be excellent model for studying normal develop-
ment and cancer formation. They provide a highly reproduc-
ible in vitro model for studying proliferation fate choice and 
cell death in the CNS.
Primary brain tumors are a diverse group of neoplasms 
afflicting both children and adults and are among the human 
cancers with the poorest outcome (1). Currently there are no 
known modifiable risk factors identified for brain tumor pre-
vention although extensive use of cell phones has been sug-
gested as a possible risk factor (2). Current statistical data 
demonstrate that there is a 0.5 to 0.6% life time risk to be 
diagnosed with a malignant brain tumor. In children, brain 
tumours are the second commonest type of cancer (17% of 
all childhood cancer) and cause 25% of cancer deaths.
Due to the recent advances in stem cell biology, a new in-
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sight has been gained into understanding the cellular mecha-
nisms that explain the origin and drive the growth of brain 
tumours. It has been demonstration that human brain tumors 
are comprised by a diverse cellular pool having a functional 
hierarchy similar to the normal brain. Among other cell types 
there is a population of tumor stem cells aberrantly matur-
ing into more differentiated cancer cells that lose the ability 
to proliferate. The discovery of brain tumor stem cells has 
important implications for brain tumor research and the de-
velopment of effective treatment targeting the cellular source 
for cancer growth.
Cellular hierarChy of The Brain anD Brain CanCer 
Cells in normal somatic tissues are organized in hierarchical 
system based on their potential for self-renewal and level of 
differentiation. Now many reports show that human brain tu-
mours share some of the characteristics of this hierarchy (3). 
The discovery of CNS stem cells in the mammalian brain has 
laid the foundations for designing experiments to test whether 
this hierarchy also exists in human brain tumors. CNS stem 
cells are defined as rare cells in the brain that are capable 
of extensive self-renewal, proliferation and multilineage dif-
ferentiation (4,5). Central nervous system stem cells can be 
isolated from the embryonic or adult mammalian brain (6,7).
The terms “progenitor cell” and “stem cell” have often 
been equated, but currently they are used to describe distinct 
cell types with unique characteristics. Like stem cells, pro-
genitor cells have a capacity to self renew and differentiate 
into a specific type of cell. In contrast to stem cells, however, 
they have a limited capacity for self-renewal and are pre-
programmed to differentiate into a specific mature cell type. 
Thus most progenitors are described as unipotent or multipo-
tent. The opposition between self-renewal and differentiation 
mechanisms in stem cells has been attributed to two distinct 
types of division – symmetric and asymmetric (8). CNS stem 
cells divide symmetrically for self-renewal. To generate neu-
rons, astrocytes, oligodendrocytes they divide asymmetri-
cally (Figure 1a and b) (9,10). Postnatally, CNS stem cells 
reside in the subventricular zone (SVZ) along the walls on 
the lateral ventricles throughout life and can be found even 
in old age (9,11,12). Stem cells (or more restricted progeni-
tors) have also been demonstrated in the adult hippocampus 
(13-15).
CNS stem cells and progenitors are mainly defined by the 
expression of markers such as nestin, an intermediate fila-
ment protein (16). In vitro, nestin expression is lost with dif-
ferentiation of CNS stem cells into neurons and glia. In vivo, 
nestin expression is found postnatally in proliferative zones, 
such as the SVZ (17). Direct isolation of CNS stem cells from 
the developing brain can be done with flow cytometry for the 
cell surface marker, CD133 (18). CD133 is expressed in the 
SVZ of developing mammalian brain with a more restricted 
expression than nestin (19–21). CD133 expressing cells have 
marked stem cell activity as determined in clonogenic neuro-
sphere assays (18).
oriGin of Brain Tumour CellS
Identifying the cell of origin for brain tumors, we will enable 
us to understand the molecular alterations leading to cancer, 
and would provide the knowledge base for an effective for 
treatment. The cell that is transformed may have important 
bearings on the behavior of the neoplasm and therefore may 
also affect the patient prognosis. For a long period of time the 
dominating view postulated that brain tumors originate from 
mature cell types like astrocytes, oligodendrocytes and neu-
rons. Some neuropathological observations, however, have 
suggested that tumour cells might be stem cell or progenitor 
cell derived. This theory was supported by the expression of 
markers of mature cell types in the tumour cells. Specifically 
brain tumours often comprise morphologically heterogene-
ous cells, with varying numbers of less-differentiated cells 
which can be identified by the neural precursor marker nestin 
(22, 23) as well as cells expressing differentiated neural line-
age markers (24), suggesting that the transformed cell has 
multipotentiality. Clinically, human brain tumours are also 
known to frequently arise near the SVZ. Based on this find-
ing, as early as 1944, Globus and Kuhlenbeck (25) suggested 
that the SVZ contains “embryonal rests” giving rise to brain 
tumours. A combined mutant mouse model deficient in p53 
with LoxP–Cre engineered conditional allele of NF1 in the 
CNS stem/progenitor cell compartment yielded glioblastoma 
in 100% of mice (26). Notably, before full-blown tumours 
arise, preneoplastic changes are seen in the SVZ, suggest-
ing that cells targeted for transformation came from a GFAP 
positive cell in the stem cell compartment. 
Recent experiments show that glioblastoma oncogenesis 
takes place in CNS stem cells, but not in astrocytes or other 
mature cell types (Fig. 2). The effect of glioma derived onco-
genes has been tested in different brain cell compartments in 
vivo through retroviral gene transfer. Tissue specificity was 
controlled by the promoter driving oncogene expression. In 
these experiments, nestin expressing cells (CNS stem cells 
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Figure 1. (A). Schematic representation of the hierarchical decisions in the developing brain. (B). Schematic representation of 
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and progenitors) have been more receptive to oncogenic 
transformation than differentiated brain cells (27,28). Ex-
pression of combinations of Ras and Akt oncogenes more 
potently induced glioblastoma using a nestin promoter than a 
glial fibrillary acidic protein (GFAP) promoter.
As in cortical gliomas, recent studies on cerebellar stem 
cells purified based on CD133 expression, suggest that these 
cells are also possible cells of origin for medulloblastomas 
(29). 
Interestingly, in the skin, the tumour phenotype was highly 
depended on the cell compartment in which an oncogene (H-
Ras) was expressed (30, 31). Benign tumours resulted from 
H-Ras overexpression in differentiated layers of the skin, but 
invasive carcinomas resulted from H-Ras expressed in skin 
stem cells containing areas. Thus, it might be speculated that 
there are different cells of origins for different types of brain 
tumors, more benign tumors arising from restricted progeni-
tors or differentiated cells and aggressive malignant tumors 
from stem cells or early progenitors.
Brain Tumour STem CellS
Several groups studying human brain tumours identified 
small numbers of cells with clonogenic potential based on 
the neurosphere assay (32-39). In culture, these brain tumour 
cells form self-renewing neurosphere-like colonies, and they 
have an ability to differentiate into one or more neural line-
ages. In neurosphere conditions, brain tumour cells express 
nestin and CD133. Brain tumors grown as spheres also ex-
press molecular markers associated with neural precursors, 
such as Sox2, Bmi1 (33), Notch, Emx2, Pax6 (37) and Jag-
ged1 (32). Following differentiation, they express markers of 
mature neurons, astrocytes and oligodendrocytes.
Although there is a predominant cell type in which brain 
tumour cells differentiate often multiple differentiated line-
ages are found in an individual tumour. For example, expand-
ed nestin positive astrocytoma cells differentiate into GFAP 
positive astrocytes after plating in serum. However, glioblas-
tomas can differentiate into GFAP positive astrocytes and a-
III-tubulin positive neurons (32,34-38), suggesting that they 
are derived from a cell that has multilineage differentiation 
capacity. Brain tumor cells grown in neurosphere conditions 
have now been very recently shown to more faithfully repli-
cate the phenotype and genotype of primary patient tumors 
compared with serum-derived lines (39). The sphere-forming 
population was then found to reside in the fraction of primary 
brain tumour cells that express the CNS stem cells/precur-
Figure 2. Schematic representation of the experiments supporting the neural stem cell origin of gliomas (for more information 
see Holland et al. Nat Genet 2000; 25:55-57).
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Figure 3. Schematic representation of the experiments supporting the existence of glioma stem cells (for more information see 
Singh et al. Nature 2004; 432:396–400; Bao et al. Nature 2006; 444:756-760).
sor cell surface marker CD133 (18, 34-36). CD133 positive 
cells represent a subpopulation of cells in brain tumors with 
a frequency of as low as 1% or less in low-grade tumors to as 
high as 30% in highly aggressive glioblastomas, with a rela-
tively close correlation with clonogenic frequency based on 
a primary neurosphere-forming assay. However, within one 
pathological type of brain tumor, such as glioblastoma, the 
frequency of expression of this marker could be extremely 
variable, from 5 to 30% in different patients’ tumors.
The importance of the CD133 positive fraction in gliob-
lastomas is yet to be determined. These CD133 positive 
cells could differentiate to express mature neural cell lineage 
markers in vitro. The definitive demonstration of a cancer 
stem cell requires an in vivo demonstration that the alleged 
cancer stem cell is capable of re-initiating and maintaining 
growth of a tumor that resembles the original tumor. Injec-
tion of 102-103 uncultured malignant brain tumor cells, pu-
rified by magnetic bead sorting for CD133, could initiate 
formation of a serially transplantable tumor in the brains of 
NOD/SCID mice that was a phenocopy of the patient’s origi-
nal tumor, whereas injection of 105 CD133 negative cells did 
not cause brain tumours (36) (Fig. 3). Tumor xenografts dif-
fusely infiltrated into the brain, which is a hallmark of ma-
lignant brain tumors. Purified populations of CD133 positive 
cells injected into the brains of NOD/SCID mice induced 
tumors that were heterogeneous and had a minority of cells 
that expressed CD133, suggesting differentiation in vivo. Im-
portantly, sphere-forming glioblastoma cells have also been 
shown to initiate tumors following transplantation into im-
munodeficient mice (37,38).
Although tumor stem cells are in the CD133 fraction, not 
every CD133 positive cell has stem cell properties in vitro. 
The cancer stem cell fraction will require further purification. 
The differentiation ability of tumour sphere cells or CD133 
positive cells suggests that some aspects of a normal devel-
opmental program is maintained in these neoplastic cells and 
that differentiation therapy is a potential option for brain tu-
mor treatment.
DeVeloPmenTal SiGnallinG in Brain Tumor STem 
CellS
Throughout development a brain cell is confronted with sev-
eral major decision like: (i) division versus senescence, (ii) 
symmetrical versus asymmetrical division, (iii) fate choice 
including choice between life and death, and (iv) migration. 
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the same signaling pathway controlling also normal develop-
ment and growth (40). Thus, cancer could be considered a 
disease of deregulated self-renewal where mutations in nor-
mal stem cell self-renewal pathways give rise to abnormal 
proliferation and cancer growth.
     Recent studies have now revealed a number of molecu-
lar mechanisms regulating stem cell self renewal and prolif-
eration. There is particular interest in the Notch (41-45), Son-
ic hedgehog (Shh; 46-53) and Wingless (54-59) pathways as 
these have been shown to play a particularly important role 
in normal stem cell self-renewal as well as in cancer growth 
when these pathways are deregulated. As well, homeobox 
transcription factors, such as HoxB4 (60, 61), the PTEN 
phosphatase protein (62) and the polycomb group of tran-
scriptional repressors (Bmi-1; 63-67), have been implicated 
in normal and cancer stem cell self-renewal. In particular, 
Bmi1 seems to be a target of Shh signaling and is expressed 
in human medulloblastomas (68), and Bmi1 deficiency in 
adult mice results in reduction of neurosphere formation 
(65,69). A role for Notch in human brain tumors is emerging, 
with finding Notch receptor and ligand transcripts in cultures 
of gliomas (32) or protein expression in primary glial tumors 
(70), and also in medulloblastomas where Notch1 or 2 tran-
scripts have been shown to be increased in patient specimens 
(71,72). Overexpression of Notch2-IC increases proliferation 
of medulloblastoma cell lines (71) and medulloblastoma cell 
line growth has been shown to be suppressed by g-secretase 
inhibitor or a soluble Dll-1 treatments (72). RNA interference 
mediated downregulation of Notch receptors and ligands in-
hibits glioma cell line proliferation and induces apoptosis. 
Interestingly, overexpression of an activated Shh co-receptor 
smoothened in the cerebellum causes activation of Notch 
pathway in the resulting tumours, suggesting crosstalk be-
tween these pathways (72). The role for Shh signaling in hu-
man medulloblastomas has been clearly established (73,74), 
with the finding of mutations in multiple Shh pathway mem-
bers, Ptc1 (75-77), Smo (78,79) and SuFu (80), in these neo-
plasms, and through the occurrence of medulloblastomas in 
Ptc1C/Kmice (81). Interestingly, human brain tumour cell 
lines with a variety of phenotypes (not only medulloblas-
toma) express all three Gli genes, the transcriptional effec-
tors of Shh signaling; and brain tumor cell lines of differ-
ent phenotypes are inhibited by the Shh pathway inhibitor 
cyclopamine (48,73). Interestingly, Gli1 was initially found 
to be amplified in a glioblastoma line, although this phenom-
enon has not been seen in primary glioblastomas (82). Recent 
findings that the Shh pathway remains active in adult tissues 
(particularly in the brain; 50,51) and plays a role in specific 
adult cancers (GI tract, pancreas, skin; 74) suggest that Shh 
could play a role in tumours of the brain other than childhood 
medulloblastomas. As brain tumours seem to be organized as 
stem cell hierarchies, further studies of these pathways in the 
context of purified brain tumour stem cells will likely bring 
further understanding to brain tumours.
ConCluDinG remarKS
Malignant gliomas develop through genetic dysregulation of 
several distinct genetic pathways. Understanding these path-
ways is crucial for developing more effective chemotherapy. 
Identifying the cellular origin of these tumors is another key 
issue for developing cell specific therapeutic targets.
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